WuXi Biologics (Cayman) Inc.
WuXi Biologics (Cayman) Inc. (HKSE: 2269) is trading at HK$53.00, about ₹649 at today's HKD/INR rate, as of 25 Sep 2026, 4:08 AM ET, up 2.12% today. Indian residents can buy WuXi Biologics (Cayman) from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$51.60
Today's high
HK$53.40
52 week low
HK$28.48
52 week high
HK$54.45
2269 opened at HK$51.95, closed previously at HK$51.90, and has traded between HK$28.48 and HK$54.45 over the past 52 weeks.
About
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
Key statistics
Avg. volume
34.40M
Market cap
HK$219.61B
P/E Ratio
37.46
Price-to-sales ratio
7.95
Enterprise value
CN¥181.64B
Free cash flow yield
2.36%
Debt-to-equity ratio
0.06
Return on equity
10.51%
ROIC
10.60%
Beta
0.62
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥21.79B
Earnings per share
CN¥1.16
Free cash flow
CN¥2.80B
Net profit margin
21.20%
Gross margin
47.47%
EBITDA
CN¥7.92B
Revenue growth
16.68%
Similar securities
This is not an investment recommendation
How to buy WuXi Biologics (Cayman) from India
Indian residents can buy WuXi Biologics (Cayman) shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for WuXi Biologics (Cayman) and place an order
Find WuXi Biologics (Cayman) by name or by its ticker, 2269, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. WuXi Biologics (Cayman) trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your WuXi Biologics (Cayman) position in HKD and INR. WuXi Biologics (Cayman) pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in WuXi Biologics (Cayman) from India
Trading and taxes when buying WuXi Biologics (Cayman) from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneWuXi Biologics (Cayman) does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy WuXi Biologics (Cayman) stock?
Yes. WuXi Biologics (Cayman) (2269) has been listed on the Hong Kong Stock Exchange since 2017, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one WuXi Biologics (Cayman) share cost in rupees?
One WuXi Biologics (Cayman) share is HK$53.00 — about ₹649 at an HKD/INR rate of 12.25 on 24 Sep 2026. Both the WuXi Biologics (Cayman) price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying WuXi Biologics (Cayman) from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of WuXi Biologics (Cayman)?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on WuXi Biologics (Cayman) shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the WuXi Biologics (Cayman) price. Paasa issues a capital-gains statement for your return.
Does WuXi Biologics (Cayman) pay a dividend?
No. WuXi Biologics (Cayman) does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade WuXi Biologics (Cayman) from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is WuXi Biologics (Cayman) a Hong Kong SAR China company, and does that change how it is taxed?
WuXi Biologics (Cayman) trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. WuXi Biologics (Cayman) trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare WuXi Biologics (Cayman) shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your WuXi Biologics (Cayman) holding, its cost and its closing value.
How do I sell WuXi Biologics (Cayman) and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.